Now you can get a second opinion without changing providers 😃
As you’ll see from the vid, I’ve been put through the wringer by providers. Still working through the final considerations between CAR-T and bispecific, but I spent a couple of hours studying both on the OnCo app yesterday. Biology is over my head — the information isn’t. I finished knowing what I needed for a clear, educated and doubtless decision. That’s huge!
So if your provider tells you you’ve got cancer, pull OnCo up while you’re still in the room. It’s free, no signup, and it takes you straight to the sources. Link in bio (via CareHub) or direct below. Tell your friends and your doctors.
The gap between what patients can see and what the field already knows is that big. OnCo has made that map visible
#healthtech #fuckcancer #multiplemyeloma
So this is a very cool cancer tech update…
I had my follow up appointment with my “new” oncologist at Mayo yesterday.
Since going off lenalidomide and velcade a few months ago, bone pain and exhaustion have slowly crept back in, and there are enough test results back from the bone marrow biopsy to warrant going back on treatment (which is fine by me). Although I can take the bone pain, some of it is in new places, and I’m getting a twinge every 5-10 mins or so throughout the day. Reminiscent of the sensations just before I was hospitalized, which makes me a little nervous. It’ll also knock out the active lesion in my sacrum. While terminal, there’ve been some highly effective treatment developments come to market over the last couple of years.
Preferred options include CAR-T cell therapy versus a teclistamab-based bispecific antibody approach. We discussed that CAR-T is a one-time cellular therapy but requires adequate caregiver/support arrangements and carries risks including CRS, neurotoxicity/ICANS, infections, cytopenias, secondary malignancies including T-cell lymphoma, and potential delayed neurologic toxicities.
We also discussed teclistamab, including CRS, infections/hypogammaglobulinemia with the potential need for IVIG, and generally lower risk of significant neurotoxicity compared with CAR-T; however, treatment is ongoing rather than a one-time therapy.
Both these options require stable housing and a caregiver. Of which I have neither. So, if CAR-T or bispecific therapy isn’t feasible, other options include daratumumab with carfilzomib or an IMiD/CELMoD-based regimen such as pomalidomide or iberdomide, recognizing that these may be less effective in this setting. A potential complication is the jawbone necrosis which needs attention.
I’d spoken with him about my CareHub project at my previous appointment, and was excited to share that we’d just integrated OnCo into the operating platform, and would do some further research before making a decision on Monday. OnCo is an open source cancer database compiled by @judegomila, and something the cancer community has needed forever - from patients to practitioners. He hadn’t heard of it before - it’s that new!
The cool bit is that I received a full and perfect transcript of our meeting through the Mayo portal within a couple of hours, and I looked everything up in OnCo to corroborate. His recommendations stacked up.
I encourage anyone dealing with cancer to explore OnCo for their own condition. 474 cancers are covered, along with symptoms, approved treatments, active clinical trials, drug side effects and lots more. It’s a truly magnificent tool that takes you to sources of truth - something that’s hard to come by these days.
There’s a link in 🧵 that’ll take you right there. It’s free, and you don’t have to sign up for anything. If you’ve got the courage to mention it, I’d suggest your oncologist becomes familiar with it, too.
#fuckcancer #healthtech #healthequity
Something 70% of you may want to consider, is a clinical trial for your chronic disease ♦️
If you have a terminal disease, considering a trial on diagnosis is tricky decision to make. Do you go with safety or all in?
I've been assessing a few options over the last few days while at a treatment crossroads with multiple myeloma, a terminal cancer.
Although myeloma treatments are superior to what they were 7 years ago, the decision on whether to consider a trial still a tricky one - and with potentially less time on your hands for a reversal.
I made these 2 overview slides to give you the gist (not medical advice, etc) ♦️
Eat your veggies
#myeloma #Clinicaltrial #fuckcancer
Current SARS-CoV-2 wastewater levels are higher than 82% of all days since the WHO declared the pandemic onset on March 11, 2020.
"During COVlD" is now.
The brilliant thing about facts, is they're undeniable.
1 - This is a picture of ignorami.
2 - In the 🧵 is the latest data on daily infections from @michael_hoerger#rocksintheirheads
Einfach Deutsch und Englisch zu sprechen bedeutet, dass du dazu beitragen kannst, die Versorgungslücke bei chronischen Erkrankungen weltweit zu schließen.
Mach doch bei unserem Sprach-Audit mit und hilf uns, unsere deutschen Übersetzungen zu überprüfen! Den Link findest du im 🧵
David Lennard
Gründer, CareHub
#cancerawareness #language #medtech